
Neurolixis Publishes Positive Phase 2A Trial Results for NLX-112 in Parkinson’s Disease
NLX-112 Shows Groundbreaking Dual Efficacy in Reducing Levodopa-Induced Dyskinesia and Parkinsonian Motor Symptoms PARK RIDGE, NJ, UNITED STATES, March 18, 2025 /EINPresswire.com/ -- Neurolixis, Inc., a clinical-stage biopharmaceutical company …